PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2017 | 7 | 2 | 78-82
Article title

Cardiovascular complications of selected antibodies used in oncological immunotherapy

Content
Title variants
Languages of publication
EN
Abstracts
EN
Immunotherapy supports other therapeutic methods and is an important element in the fight against cancer. Its main tasks include stimulation and guidance of the immune system to fight cancer, inhibition of the mechanisms that block the immune system, and direct destruction of neoplastic cells. Different from chemotherapy or hormonal therapy, its mechanism of action is associated with a different profile of adverse events. HER2 receptor inhibitors may cause symptoms of heart failure, which usually recede, once the treatment has been discontinued. Bevacizumab, an anti-VEGF antibody, induces numerous cardiovascular complications, including arterial hypertension, arterial embolism, haemorrhage and haemoptysis as well as venous thromboembolism.
Discipline
Publisher

Journal
Year
Volume
7
Issue
2
Pages
78-82
Physical description
Contributors
References
  • 1. Melero I, Berman DM, Aznar MA et al. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer 2015; 15: 457-472.
  • 2. Sharkey RM, Goldenberg DM. Targeted therapy of cancer: new prospects of antibodies and immunoconjugates. CA Cancer J Clin 2006; 56: 226- 243.
  • 3. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
  • 4. Pinder MC, Duan Z, Goodwin JS et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007; 25: 3808-3815.
  • 5. Tan-Chiu E, Yothers G, Romond E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005; 23: 7811-7819.
  • 6. Slamon DJ, Eiermann W, Robert N. BCIRG 006: 2nd interim analysis phase III randomized trial Phase III comparing doxorubicine and cyclophosphamide followed by docetaxel (AC-T) with doxorubicine and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients. Breast Cancer Res Treat 2006; 100: General Session 2; Abstract S2.
  • 7. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel and vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-820.
  • 8. Shah MA. Update on metastatic gastric and esophageal cancers. J Clin Oncol 2015; 33: 1760-1769.
  • 9. Cardinale D, Colombo A, Bacchiani G et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015; 131: 1981-1988.
  • 10. Cardinale D, Colombo A, Lamantia G et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010; 55: 213-220.
  • 11. De Azambuja E, Bedard PL, Suter T et al. Cardiac toxicity with anti-HER-2 therapies: what have we learned so far? Target Oncol 2009; 4: 77-88.
  • 12. Sendur MA, Aksoy S, Altundag K et al. Cardiotoxicity of novel HER2-targeted therapies. Curr Med Res Opin 2013; 29: 1015-1024.
  • 13. Ianello A, Ahmad A. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev 2005; 24: 487-499.
  • 14. Ranpura V, Pulipati B, Chu D et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 2010; 23: 460-468.
  • 15. [online: http://www.ema.europa.eu/docs/pl_PL/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf].
  • 16. Cameron D, Brown J, Dent R et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 2013; 14: 933-942.
  • 17. Scappaticci FA, Skillings JR, Holden SN et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99: 1232-1239.
  • 18. Tewari KS, Sill MW, Long HJ 3rd et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014; 370: 734-743.
  • 19. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542- 2550.
  • 20. Zamorano JL, Lancellotti P, Rodriguez Muñoz D et al.; Task Force Members; ESC Committee for Practice Guidelines (CPG). 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines, 2016. Eur Heart J 2016; 37: 2768-2801.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-bec14bce-18e3-4593-be15-afc6f0991a31
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.